论文部分内容阅读
目的探讨莫西沙星治疗成人支原体肺炎的临床疗效。方法选取2011年8至2013年3月的60例成人支原体肺炎患者,将其随机分为研究组与对照组,每组30例。分别采用两种不同的治疗方法进行治疗,分析其临床疗效。结果研究组总有效率为96.7%,明显优于对照组(80%),差异有统计学意义(P<0.05);研究组症状与体征消失时间明显短于对照组,差异有统计学意义(P<0.05);研究组肺炎支原体清除率与Ig M检测率明显高于对照组,差异有统计学意义(P<0.05);研究组不良反应率为23.3%,明显低于对照组(63.3%),差异有统计学意义(P<0.05)。结论莫西沙星治疗成人支原体肺炎临床疗效显著,起效快,明显缩短临床症状与体征消失时间,不良反应少,值得临床长期应用。
Objective To investigate the clinical efficacy of moxifloxacin in the treatment of adult mycoplasma pneumonia. Methods Sixty adult patients with mycoplasma pneumonia from August 2011 to March 2013 were selected and randomly divided into study group and control group, with 30 cases in each group. Were treated with two different treatment methods, analysis of its clinical efficacy. Results The total effective rate of the study group was 96.7%, which was significantly better than that of the control group (80%), the difference was statistically significant (P <0.05); the symptoms and signs of the study group disappeared significantly shorter than the control group, the difference was statistically significant P <0.05). The detection rate of Mycoplasma pneumoniae and IgM in the study group was significantly higher than that in the control group (P <0.05). The adverse reaction rate was 23.3% in the study group, which was significantly lower than that in the control group (63.3% ), The difference was statistically significant (P <0.05). Conclusion Moxifloxacin treatment of adult Mycoplasma pneumonia clinical significant effect, rapid onset, significantly shorten the disappearance of clinical symptoms and signs of time, adverse reactions, worthy of long-term clinical application.